

Montanaro European Smaller Companies Fund
Quarterly Commentary – Q2 2023**Market review**

“Things are not always what they seem”, said Phaedrus in discussion with Socrates. “The first appearance deceives many; the intelligence of a few perceives what has been carefully hidden”.

Equities delivered positive returns across most major developed markets during the first half of 2023. Yet the headline figures created something of an illusion. Not since the “Nifty Fifty” propelled the Bull Market of the early 1970s has US stock market performance been as reliant on so few names. Returns this year in the US were driven by the “Magnificent Seven”, the behemoth technology stocks: Apple; Microsoft; Alphabet; Amazon; Nvidia; Tesla; and Meta (listed in order of market capitalisation).

Together, they propelled the Nasdaq to its strongest first-half performance for 40 years and staggeringly accounted for 75% of the total gains made by world equity markets during the period. The market capitalisation of Apple again breached the \$3 trillion mark, more than the combined value of the entire FTSE-100 and more than the Russell 2000 of smaller US companies. Across the S&P 500, over 80% of the year’s return came from just 15 companies, many of them technology stocks. By contrast, the median company was flat. Pity those LargeCap managers underweight the Tech Titans.

Elsewhere, interest rates continued their rapid ascent. In the US, rates rose at their fastest pace in almost four decades, while the trajectory of tightening in the UK and Europe was also steep. *“The times they are a-changin”*, sang Bob Dylan, and it is easy to forget that just two years ago, a quarter of government debt was trading at negative yields. Investors *paid* for the privilege of lending money to governments.

While investors in smaller companies enjoyed healthy returns in the US and Europe during the last 6 months, these lagged those of the technology dominated indices. The UK remained a laggard on a global basis, the FTSE-100 index hurt by its heavy exposure to oil majors and its limited technology weighting (no *“AI hoopla”* as one Analyst pithily put it), while inflation remained stubborn and persistent.

From an asset allocation perspective, SmallCap remained unloved. Investors rarely favour smaller companies when the economic backdrop is uncertain and economists are talking about recession. Some reassurance was to be found, however, in the outperformance of Quality and Growth during the first half of the year. Investors had

not entirely forgotten the importance of fundamentals despite the cacophony of market noise.

Portfolio

The NAV of the share class declined by 0.5% in Euro terms during the quarter, an outperformance of 1.2% versus the MSCI Europe Small Cap benchmark index (in Total Return terms). During the last 6 months, the NAV rose by 4%, marginally ahead of the benchmark.

The strongest contribution during the quarter came from **Surgical Science**, the Swedish provider of simulation hardware and software used to train surgeons, which outperformed following better than expected growth in its software division. **Dechra**, the UK-based provider of veterinary drugs, was acquired by private equity firm EQT at a 44% premium. **Thule**, the manufacturer of sporting and outdoor products, traded higher as end markets, such as bikes, showed signs of recovery.

The weakest contribution came from **IMCD**, the global distributor of specialty chemicals, which traded lower on concerns of excess chemicals inventory in the economy. **Sartorius Stedim**, the provider of equipment and consumables used in the production of biologic drugs, underperformed after cutting full year guidance, citing customer inventory destocking. **Melexis**, the Belgium provider of semiconductor chips to the auto industry, also underperformed due to concerns around customer inventory destocking.

Outlook

How will the market's concentrated performance resolve itself? There may be three possible routes from here: the Magnificent Seven continue to soar (potentially at some point approaching a level so disconnected from their fundamentals that a bubble appears); they fall back to earth; or the rest of the market catches up. Which route the market embarks on may come down to whether the US economy heads towards a recession, which depresses corporate earnings. Either that or the Federal Reserve pulls off an "immaculate disinflation" – an engineered soft economic landing where inflation falls without harming the economy.

With the diversification benefits and risk profiles of certain benchmarks highly questionable (Apple constitutes 5% of the MSCI ACWI Index), we believe one thing is clear: a greater focus on alpha rather than beta will continue to be a key theme of 2023. The environment is ripe for stock picking and investors may find it prudent to increase diversification over the remainder of the year.

While investors have shunned smaller companies, we believe this part of the market should not be ignored. Valuations are more attractive than they have been for many years – certainly compared with the big technology stocks – and any sign that the macro environment is stabilising is likely to bring this area of the market some much needed momentum.

Many investors believe SmallCap can be timed with the economic cycle. In our opinion it cannot. Forecasting is difficult at the best of times and to some extent is pointless because the future is always so uncertain. As Kevin Keegan, the former-England football manager said when facing the sack after a bad result, *“I know what’s around the corner, I just don’t know where the corner is”*. Amidst a turbulent backdrop, we try to provide our clients with some certainty by sticking to our guns and focusing on holding the very best companies we can find for the long-term.

The views expressed in this article are those of the author at the date of publication and not necessarily those of Montanaro Asset Management Ltd. The information contained in this document is intended for the use of professional and institutional investors only. It is for background purposes only, is not to be relied upon by any recipient, and is subject to material updating, revision and amendment and no representation or warranty, express or implied, is made, and no liability whatsoever is accepted in relation thereto. This memorandum does not constitute investment advice, offer, invitation, solicitation, or recommendation to issue, acquire, sell or arrange any transaction in any securities. References to the outlook for markets are intended simply to help investors with their thinking about markets and the multiple possible outcomes. Investors should always consult their advisers before investing. The information and opinions contained in this article are subject to change without notice.